Literature DB >> 19116635

Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.

Manish K Aghi1, E Antonio Chiocca.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19116635      PMCID： PMC2834994          DOI： 10.1038/mt.2008.275

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  22 in total

1.  Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study.

Authors:  G R Harsh; T S Deisboeck; D N Louis; J Hilton; M Colvin; J S Silver; N H Qureshi; J Kracher; D Finkelstein; E A Chiocca; F H Hochberg
Journal:  J Neurosurg       Date:  2000-05       Impact factor: 5.115

2.  A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

Authors:  E Antonio Chiocca; Khalid M Abbed; Stephen Tatter; David N Louis; Fred H Hochberg; Fred Barker; Jean Kracher; Stuart A Grossman; Joy D Fisher; Kathryn Carson; Mark Rosenblum; Tom Mikkelsen; Jeff Olson; James Markert; Steven Rosenfeld; L Burt Nabors; Steven Brem; Surasak Phuphanich; Scott Freeman; Rick Kaplan; James Zwiebel
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

3.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.

Authors:  R Rampling; G Cruickshank; V Papanastassiou; J Nicoll; D Hadley; D Brennan; R Petty; A MacLean; J Harland; E McKie; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

4.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

5.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

Authors:  Z Ram; K W Culver; E M Oshiro; J J Viola; H L DeVroom; E Otto; Z Long; Y Chiang; G J McGarrity; L M Muul; D Katz; R M Blaese; E H Oldfield
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

6.  The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.

Authors:  V Papanastassiou; R Rampling; M Fraser; R Petty; D Hadley; J Nicoll; J Harland; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

7.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.

Authors:  James M Markert; Peter G Liechty; Wenquan Wang; Shanna Gaston; Eunice Braz; Matthias Karrasch; Louis B Nabors; Michael Markiewicz; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; George Y Gillespie
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

8.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Authors:  S Harrow; V Papanastassiou; J Harland; R Mabbs; R Petty; M Fraser; D Hadley; J Patterson; S M Brown; R Rampling
Journal:  Gene Ther       Date:  2004-11       Impact factor: 5.250

9.  Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project.

Authors:  Susan M Chang; Ian F Parney; Michael McDermott; Fred G Barker; Meic H Schmidt; Wei Huang; Edward R Laws; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew E Sloan; Mitchel Berger
Journal:  J Neurosurg       Date:  2003-06       Impact factor: 5.115

10.  Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.

Authors:  Stephen F Stanziale; Henrik Petrowsky; John K Joe; Gretchen D Roberts; Jonathan S Zager; Niraj J Gusani; Leah Ben-Porat; Mithat Gonen; Yuman Fong
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982
View more
  20 in total

1.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

2.  A cross-talk network that facilitates tumor virotherapy.

Authors:  Agnieszka Bronisz; E Antonio Chiocca
Journal:  Nat Med       Date:  2015-05       Impact factor: 53.440

3.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

4.  Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.

Authors:  Atique U Ahmed; Bart Thaci; Nikita G Alexiades; Yu Han; Shuo Qian; Feifei Liu; Irina V Balyasnikova; Ilya Y Ulasov; Karen S Aboody; Maciej S Lesniak
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

5.  Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo.

Authors:  X Chen; Y Zhou; J Wang; J Wang; J Yang; Y Zhai; B Li
Journal:  Cancer Gene Ther       Date:  2015-07-03       Impact factor: 5.987

6.  Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism.

Authors:  Alexander Muik; Inna Kneiske; Marina Werbizki; Doris Wilflingseder; Tsanan Giroglou; Oliver Ebert; Anna Kraft; Ursula Dietrich; Gert Zimmer; Stefan Momma; Dorothee von Laer
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

Review 7.  Understanding the role of tumor stem cells in glioblastoma multiforme: a review article.

Authors:  Aalya Fatoo; Michael J Nanaszko; Baxter B Allen; Christina L Mok; Elena N Bukanova; Robel Beyene; Jennifer A Moliterno; John A Boockvar
Journal:  J Neurooncol       Date:  2010-09-18       Impact factor: 4.130

Review 8.  A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme.

Authors:  Thomas Wirth
Journal:  World J Exp Med       Date:  2011-12-20

Review 9.  Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Authors:  Marianela Candolfi; Kurt M Kroeger; A K M G Muhammad; Kader Yagiz; Catherine Farrokhi; Robert N Pechnick; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

10.  Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.

Authors:  Michael J Burke; Charlotte Ahern; Brenda J Weigel; John T Poirier; Charles M Rudin; Yingbei Chen; Timothy P Cripe; M Brooke Bernhardt; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2014-10-12       Impact factor: 3.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.